Urologix, Inc. (ULGX)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Nov 25, 2025
Urologix Revenue
Urologix had revenue of $2.75M in the quarter ending March 31, 2015, a decrease of -16.71%. This brings the company's revenue in the last twelve months to $12.00M, down -19.41% year-over-year. In the fiscal year ending June 30, 2014, Urologix had annual revenue of $14.01M, down -15.00%.
Revenue (ttm)
12.00M
Revenue Growth
-19.41%
P/S Ratio
0.00
Revenue / Employee
196.70K
Employees
61
Market Cap
2.13K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2014 | 14.01M | -2.47M | -15.00% |
| Jun 30, 2013 | 16.48M | -543.00K | -3.19% |
| Jun 30, 2012 | 17.03M | 4.46M | 35.45% |
| Jun 30, 2011 | 12.57M | -2.20M | -14.89% |
| Jun 30, 2010 | 14.77M | 1.96M | 15.25% |
| Jun 30, 2009 | Pro | Pro | Pro |
| Jun 30, 2008 | Pro | Pro | Pro |
| Jun 30, 2007 | Pro | Pro | Pro |
| Jun 30, 2006 | Pro | Pro | Pro |
| Jun 30, 2005 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 122.89M |
| Glass House Brands | 196.17M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 25.83M |
| Global Cord Blood | 196.10M |
| Zomedica | 29.45M |